Security record · archived quarter
IONS
Ionis Pharmaceuticals, Inc. · Healthcare · Biotechnology
17Tracked holders
n/aΔ holders
24.68MShares held
$1.18BReported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 137 | +2 | 148.57M | $11.08B | +6 | −5 |
| Q1 2026 | 139 | -2 | 142.62M | $9.86B | +6 | −9 |
| Q4 2025 | 142 | 0 | 143.10M | $10.36B | +1 | n/a |
| Q3 2025 | 25 | +4 | 95.56M | $6.25B | +5 | −2 |
| Q2 2025 | 19 | +1 | 95.25M | $3.76B | +1 | n/a |
| Q1 2025 | 15 | -1 | 43.90M | $1.32B | +1 | −2 |
| Q4 2024 | 16 | -1 | 43.25M | $1.51B | n/a | −1 |
| Q3 2024 | 16 | -1 | 34.86M | $1.40B | n/a | −1 |
| Q2 2024 | 17 | n/a | 24.68M | $1.18B | n/a | n/a |
Who holds it · Q2 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 6.57M | n/a | $313.07M | 0.1% | n/c | 1 | SEC ↗ ×9 |
| 2 | T. Rowe Price ✦ | 3.93M | n/a | $187.51M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Tweedy, Browne ✦ | 3.45M | n/a | $164.65M | 7.6% | n/c | 1 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 2.48M | n/a | $118.45M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 5 | Capital World Investors ✦ | 2.25M | n/a | $107.33M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | ARK Investment Management ✦ | 1.36M | n/a | $64.87M | 0.6% | n/c | 1 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 1.03M | n/a | $49.00M | 0.1% | n/c | 1 | SEC ↗ |
| 8 | Norges Bank ✦ (passive) | 1.02M | n/a | $48.58M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Adage Capital Partners ✦ | 800.00K | n/a | $38.13M | 0.1% | n/c | 1 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 627.03K | n/a | $29.88M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 11 | Baillie Gifford ✦ | 260.25K | n/a | $12.40M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 12 | Renaissance Technologies ✦ | 249.51K | n/a | $11.89M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 190.78K | n/a | $9.09M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | Marshall Wace ✦ | 173.20K | n/a | $8.25M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 15 | Point72 Asset Management ✦ | 137.21K | n/a | $6.54M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Millennium Management ✦ | 128.22K | n/a | $6.11M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Gotham Asset Management ✦ | 6.26K | n/a | $298,447 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 490 holders, 170.17M shares, $11.94B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q2 2024 ·
Methodology ·
Get this via the API